Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy

Author(s): Shuai Gao, Xiaoyang Li, Jie Zang, Wenfang Xu*, Yingjie Zhang*

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 17 , Issue 6 , 2017

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Epigenetic modifications play central roles in cellular differentiation and their deregulations really contribute to tumor development. Histone deacetylase (HDAC) enzymes can exert their functions in the epigenetic regulation of gene expression related to oncogenesis via deacetylating the lysine residues of histones in the chromatin and various non-histone proteins. A majority of HDAC inhibitors (HDACIs) have been in different stages of preclinical and clinical trials with potent anticancer activity recently. Among these agents, chidamide tested as either monotherapeutic agent or in combination regimens for numerous hematological and solid malignancies has shown promising potential as an orally active subtype-selective HDACI. Herein we will highlight the progress of clinical trials of chidamide and rationally analyze those results from both preclinical and clinical studies about chidamide as an epigenetic modulator in cancer therapy.

Keywords: Epigenetic, histone deacetylase inhibitors, chidamide, hematologic and solid cancers, preclinical and clinical trials.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 05 June, 2017
Page: [802 - 812]
Pages: 11
DOI: 10.2174/1871520616666160901150427
Price: $65

Article Metrics

PDF: 124
HTML: 15